tiprankstipranks
Trending News
More News >
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
US Market

Royalty Pharma (RPRX) Income Statement

Compare
1,296 Followers

Royalty Pharma Income Statement

Last quarter (Q3 2025), Royalty Pharma's total revenue was $609.29M, an increase of 7.90% from the same quarter last year. In Q3, Royalty Pharma's net income was $288.22M. See Royalty Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 2.26B$ 2.35B$ 2.24B$ 2.29B$ 2.12B
Gross Profit
$ 2.26B$ 2.35B$ 2.24B$ 2.29B$ 1.89B
Operating Expenses
$ 971.13M$ 862.40M$ 1.93B$ 858.75M$ 296.12M
Depreciation and Amortization
$ 0.00$ 0.00$ 5.67M$ 23.00M$ 23.06M
EBITDA
$ 1.56B$ 1.89B$ 423.69M$ 1.43B$ 1.68B
Operating Income
$ 1.29B$ 1.49B$ 307.06M$ 1.43B$ 1.60B
Other Income/Expenses
$ 38.37M$ 207.94M$ -77.00M$ -189.51M$ 106.56M
Pretax Income
$ 1.33B$ 1.70B$ 230.06M$ 1.24B$ 1.70B
Net Income
$ 858.98M$ 1.13B$ 42.83M$ 619.73M$ 975.04M
Per Share Metrics
Basic EPS
$ 1.92$ 2.54$ 0.10$ 1.49$ 2.51
Diluted EPS
$ 1.91$ 2.53$ 0.10$ 1.49$ 2.51
Weighted Average Shares Outstanding
445.99M 447.60M 437.96M 414.79M 388.13M
Weighted Average Shares Outstanding (Diluted)
594.00M 602.90M 437.97M 414.80M 388.13M
Currency in USD

Royalty Pharma Earnings and Revenue History